NASDAQ$ALDX
Aldeyra Therapeutics Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Announced financial results for the third quarter of 2020 and provided a corporate update.
Aldeyra Therapeutics reported a net loss of $8.9 million for Q3 2020, compared to a net loss of $18.7 million for the same period in 2019. The company's cash, cash equivalents, and marketable securities totaled $86.2 million as of September 30, 2020, which is expected to fund operations through 2022.
- Phase 3 Objective Sign Trial in Dry Eye Disease planned for Q4 2020.
- Phase 2 Clinical Trials of ADX-629 in COVID-19, Atopic Asthma, and Psoriasis expected to start in Q4 2020.
- Top-line results from the Phase 3 INVIGORATE Clinical Trial in Allergic Conjunctivitis expected in the first half of 2021.
- Cash, cash equivalents, and marketable securities of $86.2 million as of September 30, 2020, expected to support operations through 2022.
Headline financials
Revenue & EPS history
Aldeyra · Revenue · Quarterly
$0
Forward guidance
Aldeyra expects its cash, cash equivalents, and marketable securities as of September 30, 2020, to be sufficient to fund operations through the end of 2022.
Tailwinds
- NDA submissions for reproxalap in dry eye disease and allergic conjunctivitis, assuming positive clinical trial results and regulatory review.
- Continuation of Part 1 of the Phase 3 GUARD Trial in PVR.
- Phase 2 clinical testing of ADX-629.
- Initiation of Phase 3 Objective Sign Trial in Dry Eye Disease Planned for the Fourth Quarter 2020
- Phase 2 Clinical Trials of ADX-629 in COVID-19, Atopic Asthma, and Psoriasis Expected to Initiate in the Fourth Quarter of 2020
Headwinds
- All of Aldeyra’s development timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, and other factors that could delay the initiation or completion of clinical trials.
- As a result of the COVID-19 pandemic, clinical site availability, staffing, and patient recruitment have been negatively affected and the timelines to complete Aldeyra’s clinical trials may be delayed.
- Delay in or failure to obtain regulatory approval of Aldeyra’s product candidates
- Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue.
- Risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving Aldeyra’s product candidates
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
+0.7%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+4.1%
Avg return
30 days after
47%
24 / 51 earnings
Positive
+22.7%
Q4 2026
Best reaction
-14.1%
Q4 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +22.7% | -2.3% | -6.4% | |
| Q3 2025 | -2.5% | +10.2% | -2.3% | |
| Q1 2025 | +0.9% | -3.6% | +72.3% | |
| Q4 2024 | +4.5% | +4.4% | -71.5% | |
| Q3 2024 | +2.2% | -11.9% | -3.3% | |
| Q2 2024 | -10.7% | -12.7% | +46.1% | |
| Q1 2024 | -1.0% | -0.7% | -8.1% | |
| Q4 2023 | -7.9% | -23.5% | +20.1% | |
| Q3 2023 | +7.7% | +24.9% | +36.8% | |
| Q2 2023 | +0.8% | -6.6% | -5.0% | |
| Q1 2023 | +3.8% | +0.8% | +4.6% | |
| Q4 2022 | -2.6% | +6.6% | +34.2% | |
| Q3 2022 | +12.2% | +9.5% | +18.5% | |
| Q2 2022 | +15.4% | +24.0% | +11.2% | |
| Q1 2022 | -7.5% | -10.2% | +4.1% | |
| Q4 2021 | +18.4% | +19.4% | +9.1% | |
| Q3 2021 | +10.4% | +6.9% | -6.8% | |
| Q2 2021 | +11.1% | +8.4% | +4.3% | |
| Q1 2021 | +4.3% | +4.8% | +5.6% | |
| Q4 2020 | +3.6% | -3.1% | -0.3% | |
| Q3 2020 | -1.6% | -1.6% | +5.7% | |
| Q2 2020 | -4.4% | -11.4% | -21.6% | |
| Q1 2020 | -2.7% | +14.3% | +64.8% | |
| Q4 2019 | -10.0% | -27.6% | -15.4% | |
| Q3 2019 | -1.7% | +1.0% | -21.6% | |
| Q2 2019 | -4.2% | -0.7% | -9.4% | |
| Q1 2019 | -2.9% | -7.0% | -14.4% | |
| Q4 2018 | +2.3% | +20.2% | +15.1% | |
| Q3 2018 | -13.1% | -11.1% | -6.2% | |
| Q2 2018 | +8.4% | +5.6% | +10.5% | |
| Q1 2018 | +2.9% | +1.7% | +0.0% | |
| Q4 2017 | -14.1% | -14.7% | -1.8% | |
| Q3 2017 | +2.6% | +4.3% | +19.8% | |
| Q2 2017 | -7.4% | -6.4% | -10.6% | |
| Q1 2017 | +7.6% | +12.7% | +17.7% | |
| Q4 2016 | -2.9% | +1.0% | -15.5% | |
| Q3 2016 | +2.7% | -3.6% | -22.5% | |
| Q2 2016 | +0.3% | -2.8% | -3.8% | |
| Q1 2016 | -3.1% | — | — | |
| Q4 2015 | -1.4% | — | — | |
| Q3 2015 | -3.2% | — | — | |
| Q2 2015 | -5.3% | — | — | |
| Q1 2015 | -1.1% | — | — | |
| Q4 2014 | -3.7% | — | — | |
| Q3 2013 | +5.3% | — | — | |
| Q3 2014 | +5.5% | — | — | |
| Q2 2013 | +15.0% | — | — | |
| Q2 2014 | -6.3% | — | — | |
| Q1 2014 | -4.6% | — | — | |
| Q1 2013 | -4.6% | — | — | |
| Q4 2013 | -4.6% | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro